+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
SUVEN

Share Price

 

 

Performance

  • Today's Low
  • ₹263
  • Today's High
  • ₹277
  • 52 Week Low
  • ₹124
  • 52 Week High
  • ₹300
  • Open Price₹269
  • Previous Close₹268
  • Volume1,535,620
  • 50 DMA₹236.42
  • 100 DMA₹212.49
  • 200 DMA₹197.00

Chart

Smart Investing Starts Here Start SIP with for Steady Growth!

Invest Now

Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -25.3
  • PEG Ratio
  • 0.4
  • Market Cap Cr
  • 6,990
  • P/B Ratio
  • 11.8
  • Average True Range
  • 16.44
  • EPS
  • 0
  • Dividend Yield
  • 0
  • MACD Signal
  • 10.62
  • RSI
  • 55.76
  • MFI
  • 40.24

Latest Stock News Updates

Suven Life Sciences to present research posters at APSS meet in US

Clinical-stage biotech will present three posters highlighting Phase 2 results and Phase 3 plans for narcolepsy treatment.

Suven Life Sciences completes 100% patient enrolment for Phase-2b MDD trial ahead of schedule

Conducted entirely in the United States, the randomised, double-blind, placebo-controlled trial aims to evaluate the safety and efficacy of Ropanicant across 195 patients at 35 sites over six weeks.

Q2FY26 Quarterly Result Announced for Suven Life Sciences Ltd.

Healthcare Services company Suven Life Sciences announced Q2FY26 results Revenue: Rs 46.97 million against Rs 66.09 million during Q2FY25. PAT: Rs -773.10 million against Rs -496.44 million during Q2FY25. EPS: Rs -3.48 for Q2FY26. Clinical development pipeline: SUVN-502 (Masupirdine) – Ongoing phase 3 study for Agitation and Aggression in Alzheimer’s type dementias in North America and Europe; Enrolling patients in sites in US and Europe. Expected completion by end of calander 2026. SUVN-G3031 (Samelisant) – Preparing to start Phase 3 clinical study for treatment of EDS in Narcolepsy by end of fiscal 2026. SUVN-911 (Ropanicant) – Ongoing Phase 2B clinical study in USA and expected completion by end of calander 2026. SUVN-D4010 (Usmarapride) – Planning for Phase 2 double blind study for the treatment of Cognition during 2026. SUVN-I6107 – Ongoing Phase 1 study for establishing safety and pharmacokinetics of the molecule. Anticipated completion by fiscal 2026. Result PDF

Financials

Technicals

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Suven Life Sciences Ltd. is a leading pharmaceutical company in India, specializing in the development of novel drug candidates and contract research services. The company focuses on CNS (central nervous system) disorders, providing innovative solutions for the global healthcare market.

Suven Life Sciences has an operating revenue of Rs. 7.11 Cr. on a trailing 12-month basis. An annual revenue growth of 20% is outstanding, Pre-tax margin of -3884% needs improvement, ROE of -46% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 14% and 41% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 10 which is a POOR score indicating inconsistency in earnings, a RS Rating of 93 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 67 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-05-13 Audited Results
2026-01-29 Quarterly Results
2025-11-11 Quarterly Results
2025-08-13 Quarterly Results
2025-05-13 Audited Results & Preferential issue

Shareholding Pattern

70.15%
1.79%
0.91%
0%
19.45%
7.7%

FAQs

share price is ₹265 As on 22 June, 2026 | 23:29

The Market Cap of is ₹6989.9 Cr As on 22 June, 2026 | 23:29

The P/E ratio of is -25.3 As on 22 June, 2026 | 23:29

The PB ratio of is 11.8 As on 22 June, 2026 | 23:29

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23